Medicines & Healthcare products Regulatory Agency

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
gov.uk/mhra

[redacted]

21st February 2024

Dear [redacted]

FOI 24/111

Thank you for your Freedom of Information (FOI) request dated Friday 2nd February 2024 where you requested:

- Details of Yellow Card reports related to zinc-induced copper deficiency associated with zinc or Solvazinc
- Dates of the reports

I can confirm that we do hold this information however it is exempt from release under Section 21 of the FOIA (Information accessible by other means), as this is already publicly available and can be found on our website via our interactive Drug Analysis Profiles (iDAPs).

iDAPs allow users to view all adverse reactions reported for a particular drug substance and also filter the reports so the charts and tables display subsets of the data, such as limiting the year reports are received by the Agency. There is guidance at the bottom of each iDAP page around the interpretation of this information provided on the website which is important to read and understand. It is particularly important to note that reports are not confirmed side effects to a medication and that incidence cannot be derived since a number of factors influence reporting of adverse drug reactions (ADRs).

In order to view reports for copper deficiency specifically, please use the table at the bottom of the above linked webpage and drill into the reaction terms via the following: Metabolism and nutrition disorders > Iron and trace metal metabolism disorders > Copper metabolism disorders.

I hope the information provided is helpful, but if you are dissatisfied with the handling of the part of your request handled under FOI, you have the right to ask for an internal review. Internal

review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team,
Safety and Surveillance
Medicines and Healthcare products Regulatory Agency

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF